Empagliflozin for treating type 2 diabetes
Status Complete
Process STA
Referral date October 2013
Topic area
  • Endocrine, nutritional and metabolic


Key events during the development of the guidance:

Date Update
10 September 2014

In the Appraisal Consultation Document (ACD) for the appraise of empagliflozin combination therapy for treating type 2 diabetes [ID641], the Appraisal Committee requested further analyses from the company.

Boehringer Ingelheim has indicated that new economic analyses will be submitted in response to this request. In order to allow a complete set of analyses as requested by the Committee to be produced, and for those analyses to be reviewed by the Evidence Review group, NICE has agreed an extension in timings. Therefore the second Committee Meeting has been rescheduled to 25 November 2014.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance